Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Bichet

Showing results (51-60 of 144) with videos related to

Pageof 15
Sort By:
American Journal of Physiology. Renal Physiology|March 7, 2014
The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptorsKristian Vinter Juul, Daniel G Bichet, Søren Nielsen, et al.
Canadian Journal of Kidney Health and Disease|January 16, 2026
Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR RegistryPhilip McFarlane, Daniel G Bichet, Ahsan Alam, et al.
NDT Plus|May 8, 2015
A novel disease-causing mutation in AVPR2: Q96HMathieu Lemaire, David Chitayat, Denis F Geary, et al.
Clinical Cardiology|July 1, 2018
Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional studyLu Zhao Di, Maxime Pichette, Réginald Nadeau, et al.
American Journal of Physiology. Cell Physiology|November 3, 2006
Elaboration of a novel technique for purification of plasma membranes from Xenopus laevis oocytesAlexandre Leduc-Nadeau, Karim Lahjouji, Pierre Bissonnette, et al.
Scientific Reports|September 20, 2016
Functional Recovery of AQP2 Recessive Mutations Through Hetero-Oligomerization with Wild-Type CounterpartAbdulah El Tarazi, Yoann Lussier, Sandra Da Cal, et al.
Blood|July 16, 2011
Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney diseaseJon D Blumenfeld, Jeffrey Tepler, Andreas Mauer, et al.
Clinical Immunology (Orlando, Fla.)|June 20, 2006
Severe combined immunodeficiency associated with nephrogenic diabetes insipidus and a deletion in the Xq28 regionArnon Broides, Bettina H Ault, Marie-Françoise Arthus, et al.
Molecular Endocrinology (Baltimore, Md.)|May 29, 2004
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059Virginie Bernier, Monique Lagacé, Michèle Lonergan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2002
Body compartment volumes and composition after giving a vasopressin antagonist: changes are revealed by a tonicity balanceMogamat Razeen Davids, Yeouda Edoute, Jean-Pierre Mallie, et al.
Pageof 15

Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
American Journal of Physiology. Renal Physiology|March 7, 2014
The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptorsKristian Vinter Juul, Daniel G Bichet, Søren Nielsen, et al.
Canadian Journal of Kidney Health and Disease|January 16, 2026
Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR RegistryPhilip McFarlane, Daniel G Bichet, Ahsan Alam, et al.
NDT Plus|May 8, 2015
A novel disease-causing mutation in AVPR2: Q96HMathieu Lemaire, David Chitayat, Denis F Geary, et al.
Clinical Cardiology|July 1, 2018
Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional studyLu Zhao Di, Maxime Pichette, Réginald Nadeau, et al.
American Journal of Physiology. Cell Physiology|November 3, 2006
Elaboration of a novel technique for purification of plasma membranes from Xenopus laevis oocytesAlexandre Leduc-Nadeau, Karim Lahjouji, Pierre Bissonnette, et al.
Scientific Reports|September 20, 2016
Functional Recovery of AQP2 Recessive Mutations Through Hetero-Oligomerization with Wild-Type CounterpartAbdulah El Tarazi, Yoann Lussier, Sandra Da Cal, et al.
Blood|July 16, 2011
Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney diseaseJon D Blumenfeld, Jeffrey Tepler, Andreas Mauer, et al.
Clinical Immunology (Orlando, Fla.)|June 20, 2006
Severe combined immunodeficiency associated with nephrogenic diabetes insipidus and a deletion in the Xq28 regionArnon Broides, Bettina H Ault, Marie-Françoise Arthus, et al.
Molecular Endocrinology (Baltimore, Md.)|May 29, 2004
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059Virginie Bernier, Monique Lagacé, Michèle Lonergan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2002
Body compartment volumes and composition after giving a vasopressin antagonist: changes are revealed by a tonicity balanceMogamat Razeen Davids, Yeouda Edoute, Jean-Pierre Mallie, et al.
Pageof 15